Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Date:4/21/2009

- Safety and Tumor Response Data from Dose-Escalation Study Presented at

American Association for Cancer Research's 100th Annual Meeting 2009 -

SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 dose-escalation study of picoplatin in patients with metastatic colorectal cancer (CRC). Results demonstrated that picoplatin can be safely administered in combination with 5-fluorouracil and leucovorin (FOLPI) as a first-line option for CRC. Based on the safety data as well as the promising clinical activity observed in this trial, Poniard initiated a randomized, controlled, proof-of-concept Phase 2 trial to evaluate picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed in May 2008.

"Several treatment options for metastatic CRC have been introduced in the last decade and have resulted in enhanced survival when administered as a first-line treatment. However, these treatments can cause serious side effects, including severe neuropathies that prevent patients from participating in routine daily activities and may lead to discontinuing therapy," said Robert De Jager, M.D., chief medical officer of Poniard. "We are encouraged by these preliminary results, which continue to show that picoplatin given once every four weeks as part of the FOLPI regimen is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen; both regimens have similar anti-tumor activity in first-line metastatic CRC. We are continuing to observe the study participants and look forward to presenting initial pro
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
2. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
3. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
4. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
8. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
9. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
10. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
11. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... 2014 The custom stainless steel fabrication ... Show 2014. The Boston Area Chapter of ISPE (International ... day-long event for Wed., Oct. 1 at Gillette Stadium ... the largest in ISPE Boston’s long history, with more ... attendees expected. , HOLLOWAY AMERICA President David Simpson ...
(Date:9/30/2014)... 30, 2014 On September 11, Pharma IQ ... in anticipation of a session that he will lead on ... scheduled for February 17-18, 2015 in London. In the ... asked Dr. Sherley to respond to several questions on the ... to evaluating stem cell toxicity, and future trends in the ...
(Date:9/30/2014)... September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, Pennsylvania, ... and Safety (ACRES), a Massachusetts non-profit charitable ... alliance agreement, setting the stage for multiple collaborative ... clinical research quality and safety through specialized nursing ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... , MONTREAL, Dec. 7 /PRNewswire/ - Enerkem Inc. ... been selected by the U.S. Department of Energy (DOE) to ... of its waste-to-biofuels facility to be located in Pontotoc, Mississippi. ... been selected in the larger demonstration scale project category of ...
... 7 ATS Medical, Inc. (Nasdaq: ATSI ), ... services today announced it has received CE Mark approval ... the European Union, indicating it is compliant with relevant ... The Enable valve is the first surgical aortic valve ...
... ... develop systems biology-driven therapeutics to include small molecules, chemotherapy and RNAi candidates and ... ... announced today that it has acquired Hermes Biosciences, Inc. a private biotechnology company ...
Cached Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
(Date:9/29/2014)... Dr. Cristin Samper, president and CEO of the ... San Carlos. , The Order of San Carlos ... who have made outstanding contributions to the country, ... An international authority on conservation biology and environmental ... Residence in New York to receive the honor ...
(Date:9/29/2014)... in Behavioral Brain Research provides novel insight ... result of chronic alcohol exposure that can lead to ... and research indicate that individuals with alcohol use disorders ... when people are actively drinking, when they are going ... "Sleep-wake disturbances can last for months, or even years, ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2
... Scientists have new information about the complex genetic ... of cognitive decline and dementia in the elderly. ... January issue of the American Journal of ... to look for genes associated with this devastating ...
... cancer cells for the whereabouts of an important tumor-suppressor, they ... broth instead of muscling its way out to the cells, ... of delinquency puzzled scientists for a long time until ... Medicine felt compelled to genetically grab the protein by the ...
... clinical trial suggests that long-term use of candesartan, a ... the symptoms of genetic heart disease. The related ... on left ventricular hypertrophy and function in non-obstructive hypertrophic ... issue of The Journal of Molecular Diagnostics . ...
Cached Biology News:Scientists make strides toward defining genetic signature of Alzheimer's disease 2Johns Hopkins scientists pull protein's tail to curtail cancer 2
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Recombinant Feline IL-2, CF...
Recombinant Equine IL-4, CF...
Recombinant Rat Leptin, CF...
Biology Products: